DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Real World Brand Tracker: Oncology

Analyze the success of immune checkpoint inhibitors (ICIs) in the U.S. with claims data to refine your oncology brand strategies

  • Understand shifting market dynamics and how events impact use across indications
  • Track and visualize payer metrics for ICI reimbursement insights over time, including total claim amount submitted and total claim paid
  • Optimize clinical trial strategies based on rapidly evolving standards in treatment practices
  • Uncover pockets of opportunity for improved penetration, and recognize where and why ICI brands are performing poorly

 

Schedule a demo

“ICIs are transforming the oncology landscape at an incredibly rapid pace, and every oncology company, even those not developing ICIs, needs to understand the shifting market dynamics because ICIs will affect their brands.”

Andrew Merron

Ph.D., Executive Director, Oncology and Biosimilars

Methodology

  • U.S. patient-level claims data for all FDA-approved ICIs
  • Monthly data update and analysis
  • Strategic insights gleaned from data by DRG’s in-house Oncology experts